Open Access
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
Marc Humbert,Richard Beasley,J. Ayres +2 more
- pp 425-434
About:
The article was published on 2017-01-01 and is currently open access. It has received 848 citations till now. The article focuses on the topics: Omalizumab.read more
Citations
More filters
Journal ArticleDOI
Omalizumab in Asthma: An Update on Recent Developments
Marc Humbert,William W. Busse,Nicola A. Hanania,Philip J. Lowe,Janice Canvin,Veit J. Erpenbeck,Stephen T. Holgate +6 more
TL;DR: Results from recent pooled data from randomized clinical trials and from a large prospective cohort study provide reassurance about the long-term safety of omalizumab.
Journal ArticleDOI
''Real-life'' effectiveness of omalizumab in patients with severe persistent allergic asthma: The PERSIST study *
Guy Brusselle,Alain Michils,Renaud Louis,Lieven Dupont,B. Van de Maele,A. Delobbe,Charles Pilette,Christopher S. Lee,Christopher S. Lee,Sandra Gurdain,Stefaan Vancayzeele,P. Lecomte,Christine Hermans,Karen MacDonald,MinKyoung Song,Ivo Abraham +15 more
TL;DR: Under real-life conditions, omalizumab is effective as add-on therapy in the treatment of patients with persistent severe allergic asthma, and better physician-rated effectiveness, greater improvements in quality of life, greater reductions in exacerbation rates, and greater reduction in healthcare utilization are reported.
Journal ArticleDOI
The eXpeRience registry: the 'real-world' effectiveness of omalizumab in allergic asthma.
TL;DR: The results from eXpeRience indicate that omalizumab was associated with improvements in outcomes in patients with uncontrolled persistent allergic asthma; these improvements were consistent with the results of clinical trials.
Journal ArticleDOI
Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE-mediated) asthma.
TL;DR: The omalizumab-IgE binding model is predictive for free IgE and demonstrates a nonlinear time-dependent relationship betweenfree IgE suppression and clinical outcomes in asthma.
Journal ArticleDOI
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma
Matthias V. Kopp,Eckard Hamelmann,S. Zielen,W. Kamin,K.-C. Bergmann,C. Sieder,S. Stenglein,S. Seyfried,Ulrich Wahn +8 more
TL;DR: The treatment of allergic asthma by specific immunotherapy (SIT) is hampered by potential side‐effects and may need to be switched to a more targeted approach.
References
More filters
Journal ArticleDOI
Evaluation of impairment of health related quality of life in asthma: development of a questionnaire for use in clinical trials.
Elizabeth F. Juniper,Gordon H. Guyatt,Robert S. Epstein,Penelope J. Ferrie,Roman Jaeschke,T K Hiller +5 more
TL;DR: A questionnaire suitable for all adults with asthma and designed to be responsive to within subject change and therefore may be used as a measure of outcome in clinical trials in asthma is developed.
Allergy, rhinitis, other respiratory diseases Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
William W. Busse,Jonathan Corren,Bobby Q. Lanier,Margaret McAlary,Angel FowlerTaylor,Giovanni Della Cioppa,Niroo Gupta,Fort Worth +7 more
TL;DR: Omalizumab as discussed by the authors is a recombinant humanized anti-IgE mAb, which forms complexes with free IgE, blocking its interaction with mast cells and basophils.
Journal ArticleDOI
Proceedings of the ATS Workshop on Refractory Asthma Current Understanding, Recommendations, and Unanswered Questions
Sally E. Wenzel,John V. Fahy,Charles G. Irvin,Stephen P. Peters,Sheldon L. Spector,Stanley J. Szefler,Thomas B. Casale,Michelle M. Cloutier,Jack A. Elias,Mark C. Liu,Virginia Taggert +10 more
TL;DR: The proceedings of an American Thoracic Society (ATS)-sponsored workshop are hoped to serve as an aid to begin to define, understand, and manage these refractory patients.
Journal ArticleDOI
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
Markus Solèr,J. Matz,Robert G. Townley,R. Buhl,J. O'Brien,Howard Fox,J. Thirlwell,N. Gupta,G. Della Cioppa +8 more
TL;DR: Results indicate that omalizumab therapy safely improves asthma control in allergic asthmatics who remain symptomatic despite regular use of inhaled corticosteroids and simultaneous reduction in Corticosteroid requirement.